Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Articles

The vetting and authorizing of important new therapies remained productive in 2020, despite the need to devote considerable resources to dealing with COVID-19 related approvals and policies.

Despite Pandemic, FDA Ramps Up New Drug Approvals

Bayer will support the development and supply of CureVac’s COVID-19 vaccine candidate, CVnCoV.

Bayer and CureVac to Collaborate on COVID-19 Vaccine Candidate

EMA has chosen Panalgo's Instant Health Data (IHD) platform to enable rapid analyses of real-world data.

EMA to Use Panalgo’s IHD Platform for Real-World Data Analytics

Intravacc and Cristal Therapeutics have entered into a strategic collaboration for the development of novel vaccine programs against human diseases.

Intravacc, Cristal Therapeutics Collaborate on Novel Vaccine Platforms

The European Commission has granted a conditional marketing authorization to Moderna for its COVID-19 vaccine.

EC Authorizes Moderna’s COVID-19 Vaccine for European Roll-Out

Evonik has closed its acquisition of the Lactel Absorbable Polymers product line from DURECT Corporation on Dec. 31, 2020.

Evonik Closes Acquisition of Lactel Absorbable Polymers Product Line

Avacta Group has entered into a license agreement with POINT Biopharma, granting access to its pre|CISION technology for the development of tumor-activated radiopharmaceuticals.

Avacta Enters License Agreement with POINT Biopharma

The transaction will include operations located at different Novasep sites, including its Pompey, France site and sites in the United States, China, and India. 

Sartorius Acquires Novasep’s Chromatography Equipment Division 

The collaboration will utilize ViGeneron’s novel engineered AAV capsids, vgAAV, to transduce retinal cells with intravitreal injections for an undisclosed target.

Biogen and ViGeneron Collaborate on Inherited Eye Disease Gene Therapy

The new facility, to be located in Boston, MA, will contain experimental and analytical equipment for viral vector and advanced therapy process development and will expand the CDMO’s manufacturing capacity.

News